UveitisNCT01837056
Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis
An observational study of Uveitis, run by National Institute of Health, Korea.
Trial summary
Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis serum antibody to T. gondii and T. canis PCR with peripheral blood for T. gondii and T. canis PCR with aqueous humor for T. gondii and T. canis Clinical manifestation of patient with uveitis Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Uveitis
- How many people
- 98 participants
- Where
- No sites listed yet
- Study dates
- Jan 2011to Feb 2012
- How long will I take part?
- 14 Days
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patient with uveitis
Who may be able to join
- patients with uveitis
Who cannot join
- Patients with history of major ophthalmic surgery within 6 months
- antiviral, antifungal or antiparasitic therapy within 6 months
About this study
Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis
- serum antibody to T. gondii and T. canis
- PCR with peripheral blood for T. gondii and T. canis
- PCR with aqueous humor for T. gondii and T. canis
- Clinical manifestation of patient with uveitis
Read the detailed description
Consecutive patients with uveitis are enrolled in Nune Eye Hospital.
Serum ELISA
- IgM,IgG antibody to Toxoplasma gondii
- IgG antibody to Toxocara canis
PCR
- PCR with serum and aqueous humor to Toxoplasma gondii
- PCR with serum and aqueous humor to Toxocara canis Clinical characteristics
- visual acuity
- intraocular pressure (IOP)
- location and degree of inflammation
- other fundus findings were recorded questionnaire
- environment, occupation
- pet ownership, exposure to animal
- history of eating raw liver of animal, raw beef or any other raw flesh of animal.
- Conditions
- Uveitis
- Keywords
- Toxoplasma gondii, Toxocara canis
- Medical subject headings
- Uveitis
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis
proportion of patients with seropositive for Toxoplasma gondii and Toxocara canis among patients
Measured: at baseline
Secondary outcomes (1)
Number of patients with positive PCR with peripheral blood and aqueous humor to Toxoplasma gondii and Toxocara canis
Proportion of patient with positive PCR to Toxoplasma gondii and Toxocara canis
Measured: at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Apr 2013 (estimated)
- Study startJan 2011
- Primary completionFeb 2012
- Study completionFeb 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for UveitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 98 participants (actual)
- Target duration
- 14 Days
Sponsor and investigators
- Lead sponsor
- National Institute of Health, Korea
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Lim, Su Jin, Nune Eye Hospital, Seoul, Korea
- Investigators
- Su Jin Lim, MD, Principal investigator, Nune Eye Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01837056
- Sponsor's protocol ID
- Nuneuveitis
- Status last verified
- Apr 2013
- First submitted
- 12 Apr 2013
- Last updated
- 22 Apr 2013
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis
- ClinicalTrials.gov ID
- NCT01837056
- Acronym / sponsor ID
- Nuneuveitis
- Conditions
- Uveitis
- Keywords
- Toxoplasma gondii, Toxocara canis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 98 participants (actual)
- Lead sponsor
- National Institute of Health, KoreaOther government
- Study start
- Jan 2011
- Primary completion
- Feb 2012 (actual)
- Study completion
- Feb 2012 (actual)
- First posted
- 22 Apr 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis
- serum antibody to T. gondii and T. canis
- PCR with peripheral blood for T. gondii and T. canis
- PCR with aqueous humor for T. gondii and T. canis
- Clinical manifestation of patient with uveitis
Detailed description
Consecutive patients with uveitis are enrolled in Nune Eye Hospital.
Serum ELISA
- IgM,IgG antibody to Toxoplasma gondii
- IgG antibody to Toxocara canis
PCR
- PCR with serum and aqueous humor to Toxoplasma gondii
- PCR with serum and aqueous humor to Toxocara canis Clinical characteristics
- visual acuity
- intraocular pressure (IOP)
- location and degree of inflammation
- other fundus findings were recorded questionnaire
- environment, occupation
- pet ownership, exposure to animal
- history of eating raw liver of animal, raw beef or any other raw flesh of animal.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 14 Days
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patient with uveitis
Key inclusion criteria (1 listed)
- patients with uveitis
Key exclusion criteria (2 listed)
- Patients with history of major ophthalmic surgery within 6 months
- antiviral, antifungal or antiparasitic therapy within 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis
Time frame: at baseline
proportion of patients with seropositive for Toxoplasma gondii and Toxocara canis among patients
1 secondary outcome
Number of patients with positive PCR with peripheral blood and aqueous humor to Toxoplasma gondii and Toxocara canis
Time frame: at baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2013.
Related trials for Uveitis
RecruitingPhase 3
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
Behçet's Disease, Juvenile Psoriatic Arthritis
Not yet recruiting
Efficacy and Safety of Adalimumab for the Treatment of Ocular Inflammation
Non-infectious Anterior Uveitis, Non-infectious Intermediate Uveitis
RecruitingObservational study
A Study of Uveitis in Children <18 Years of Age
Uveitis
Active, not recruitingPhase 2
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative
RecruitingPhase 1
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Non Infectious Uveitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Su Jin Lim, MD principal investigator
Nune Eye Hospital
Questions about this trial
What is this clinical trial studying?
An observational study of Uveitis, run by National Institute of Health, Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of patients with positive result for serum antibody to Toxoplasma gondii and Toxocara canis (time frame: at baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2013.